Report error Found 57 Enz. Inhib. hit(s) with all data for entry = 50026818
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetEpidermal growth factor receptor(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.53E+3nMAssay Description:Inhibition of HER2More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 5.70E+3nMAssay Description:Inhibition of HER2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetAurora kinase A(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Aurora AMore data for this Ligand-Target Pair
TargetAurora kinase A(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of Aurora AMore data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of HER2More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of HER2More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of HER2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetAurora kinase A(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of Aurora AMore data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of HER2More data for this Ligand-Target Pair
TargetAurora kinase A(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of Aurora AMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of VEGFR2More data for this Ligand-Target Pair
TargetAurora kinase A(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of Aurora AMore data for this Ligand-Target Pair
TargetAurora kinase A(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of Aurora AMore data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of HER2More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of HER2More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CDK1More data for this Ligand-Target Pair
TargetAurora kinase A(Human)
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of Aurora AMore data for this Ligand-Target Pair
